Engine Biosciences

Harnessing machine learning & CRISPR to discover next-generation therapeutics

Matching the Right Patient to the Right Treatment with Machine Learning and CRISPR Gene-Editing Technology: Engine’s NetMAPPR platform combines machine learning and CRISPR gene-editing technology to uncover key biomarkers that match patients with the most effective targeted treatments. By decoding complex genetic networks, they’ve identified over 30 new precision medicine opportunities, driving innovative therapies from concept to clinic and opening doors for strategic cancer research partnerships.
Building a Robust Pipeline of Precision Medicines across Multiple Diseases: Engine is rapidly expanding its drug development pipeline with over 15 biomarker programs in clinical stages. By identifying novel drug targets and combining therapies across multiple gene pathways, Engine is advancing a diverse pipeline of next-generation treatments that promise to address unmet medical needs in oncology, neurology, and beyond.